Roche's COBAS HIV blood test cleared in Italy:
This article was originally published in Clinica
Roche Diagnostics has gained clearance to sell its COBAS AmpliScreen HIV-1 v1.5 blood test for screening HIV in Italy. The PCR-based diagnostic assay is capable of revealing very early infections that cannot be detected by currently available antibody/antigen serological assays, said the Basel, Switzerland firm. Additionally, Roche Diagnostics now has PCR-based tests approved in Australia, France, Germany and Switzerland and Italy for detecting HIV and also HCV.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.